101869-74-3

Basic information

• Product Name: Cyclohexanemethanol, 4-methoxy-
• CAS NO: 101869-74-3
• Molecular Formula: C8H16O2
• Molecular Weight: 144.214
• Mol File: 101869-74-3.mol

Chemical Properties

• CAS DataBase Reference: Cyclohexanemethanol, 4-methoxy-(CAS DataBase Reference)
• NIST Chemistry Reference: Cyclohexanemethanol, 4-methoxy-(101869-74-3)
• EPA Substance Registry System: Cyclohexanemethanol, 4-methoxy-(101869-74-3)

Safety Data

• Hazardous Substances Data: 101869-74-3(Hazardous Substances Data)

Upstream product

• 106434-94-0 1-Methoxy-4-methylencyclohexan 
• 67-56-1 methanol 
• 72581-32-9 cyclohex-3-enylmethanol 
• 3685-26-5 trans-4-hydroxycyclohexanecarboxylic acid 
• 3618-03-9 trans-4-hydroxycyclohexane-1-carboxylic acid methyl ester 
• 73873-62-8 methyl trans-4-methoxycyclohexanecarboxylate 
• 63389-93-5 trans-ethyl 4-methoxycyclohexane-1-carboxylate 
• 3618-04-0 trans-4-hydroxy-cyclohexane carboxylic acid ethyl ester 
• 73873-61-7 trans-4-methoxycyclohexane-1-carboxylic acid 
• 223677-02-9 ethyl 4-methoxycyclohexanecarboxylate 
• 123-11-5 4-methoxy-benzaldehyde 
• 137058-17-4 Methyl cis/trans-4-methoxycyclohexanecarboxylate 
• 3618-04-0 4-hydroxycyclohexyl carboxylic acid ethyl ester 
• 95233-12-8 4-methoxycyclohexylcarboxylic acid 

Downstream Products

• 120552-57-0 4-methoxycyclohexane-1-carbaldehyde 
• 141604-51-5 (4-methoxy-cyclohexyl)methyl bromide 
• 141604-43-5 2-tert-butyl-4-chloro-5-(4-methoxycyclohexyl)-methylthio-3(2H)-pyridazinone 
• 1067230-23-2 C₁₅H₂₂O₄S 
• 1067230-22-1 C₁₅H₂₂O₄S 
• 120552-57-0 (1r,4r)-4-methoxycyclohexane-1-carbaldehyde 
• 1332627-43-6 C₁₁H₂₄O₂Si 
• 120552-57-0 (1s,4s)-4-methoxycyclohexanecarbaldehyde 

Relevant articles and documents

SSAO INHIBITORS AND USE THEREOF

Provided are a compound of formula (I') or (I), a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of SSAO, a pharmaceutical composition comprising a compound of formula (I') or (I), and a method of treating or preventing a disease in which SSAO plays a role.

3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF

The present disclosure provides a compound of Formula (I′): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein Rx, X1, X2, and R1 are as defined herein, and methods of making and using same.

SUBSTITUTED 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF

The present disclosure provides a compound of Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein R1, R2, Rx, X1, X2, X3, n, n1,and q are as defined herein, and methods of making and using same.

NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF

The invention provides compounds for inhibiting glucosylceramidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds.

3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF

The present disclosure provides a compound of Formula (I′): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein R1, R2, Rx, X1, n, n1, and q are as defined herein, and methods of making and using same.

Solid dispersions containing an apoptosis-inducing agent

A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

HYDROXYL PURINE COMPOUNDS AND USE THEREOF

Disclosed are a series of hydroxyl purine compounds and the use thereof as PDE2 or TNFα inhibitors, in particular, the compounds as shown in formula (I), or tautomers or pharmaceutically acceptable salts thereof.

FACTOR XIA-INHIBITING PYRIDOBENZAZEPINE AND PYRIDOBENZAZOCINE DERIVATIVES

The invention relates to substituted pyridobenzazepine and pyridobenzazocine derivatives and to processes for preparation thereof, and also to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.

Substituted Oxopyridine Derivatives and Use Thereof in the Treatment of Cardiovascular Disorders

The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.

Tuning the chemoselective hydrogenation of aromatic ketones, aromatic aldehydes and quinolines catalyzed by phosphine functionalized ionic liquid stabilized ruthenium nanoparticles

Ruthenium nanoparticles (Ru NPs) stabilized by phosphine-functionalized ionic liquids (PFILs) were synthesized in an imidazolium-based ionic liquid using H2 as a reductant. Characterization showed well-dispersed particles of about 2.2 nm (TEM) and confirmed the PFIL stabilization of the Ru NPs (NMR). The Ru NPs stabilized by PFILs exhibited excellent activity and switchable chemoselectivity in the heterogeneous selective hydrogenation of aromatic ketones, aromatic aldehydes and quinolines under mild conditions.